TODAYRead today's current affairs →
YouTubeInstagram
Tathyo
JobsCurrent AffairsInternational RelationsPolityEconomyEducationStore
अ हिंदीSubscribe

The week's essentials, straight to your inbox

Top explainers, current affairs revision and new job alerts. No spam.

Tathyo

Current affairs, international relations, education and govt jobs — explained simply and in depth.

CategoriesCurrent AffairsInternational RelationsPolityEconomyEducationScience & Tech
ExploreSarkari JobsResultsAdmit CardStore
TathyoAboutContactPrivacy PolicyDisclaimerहिंदी संस्करण
© 2026 Tathyo. All rights reserved.RSS
Home/Science & Tech
Science & Tech

ICMR's AMR Surveillance Report 2025: Why Common Antibiotics Are Losing Their Power

The annual report of ICMR's Antimicrobial Resistance Surveillance and Research Network for 2025, reported in November 2026, shows high resistance among E. coli, Klebsiella and Acinetobacter, and for the first time includes district hospitals.

Ankit KumarAnkit Kumar · Founder & Editor, Tathyo19 Nov 2026 · 8 min read
In this article1. Why in the news?2. Background3. Key findings4. Significance5. Challenges6. Way forward7. Facts for Prelims8. Mains practice question9. FAQs10. Sources

Why in the news?

The Indian Council of Medical Research (ICMR) has published the Antimicrobial Resistance Surveillance and Research Network (AMRSN) Annual Report 2025, which covers bacterial and fungal samples collected from January to December 2025. Its findings were widely reported on 18–19 November 2026, coinciding with World AMR Awareness Week (18–24 November).

The report shows that many first-line antibiotics now work against only a minority of samples of common bacteria such as E. coli and Klebsiella pneumoniae, and that resistance to "last-resort" carbapenems remains very high in some hospital pathogens.

Background

Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi or parasites change so that medicines no longer work against them. Overuse and misuse of antibiotics in people and animals, poor infection control in hospitals, and weak sanitation all speed it up.

India's policy response so far includes:

  • Schedule H1 of the Drugs and Cosmetics Rules (in force since 2014), which restricts over-the-counter sale of certain antibiotics.
  • The "Red Line" campaign, which asks people not to use medicines marked with a red line without a prescription.
  • The National Action Plan on AMR (NAP-AMR) of 2017, followed by a second version, NAP-AMR 2.0, in 2025, built on a One Health approach covering humans, animals and the environment.

ICMR's surveillance network publishes annual data from partner hospitals, giving doctors and policymakers an evidence base for treatment guidelines.

Key findings

Scale of the 2025 report

Item Figure
Tertiary-care hospitals 30
Culture-positive isolates from tertiary centres 1,13,008
Secondary-care hospitals 34 (including 12 district hospitals, added for the first time)
Isolates from secondary centres 20,529

Most common bacteria (tertiary centres)

E. coli (24.4%), Klebsiella pneumoniae (16.9%), Pseudomonas aeruginosa (12.2%) and Acinetobacter baumannii (9.5%).

Selected susceptibility and resistance figures

Organism Finding
E. coli Susceptible to cefotaxime 18.4%, ceftazidime 24.7%, ciprofloxacin 9%
E. coli (urine) Fosfomycin 96.5% and nitrofurantoin 79.1% susceptible — these older drugs still work well
Klebsiella pneumoniae Susceptible to carbapenems only about 35–40%
Acinetobacter baumannii About 91.1% resistant to carbapenems
Staphylococcus aureus 56.8% methicillin-resistant (MRSA) at tertiary centres
Enterococci About 20% resistant to vancomycin
Salmonella Typhi Azithromycin 99.4% and ceftriaxone 96.6% susceptible, but ciprofloxacin only about 2%
Newborns (up to 28 days) Klebsiella pneumoniae was the most frequent bloodstream isolate (25.1%)

Figures as reported by The South First and Daijiworld from the ICMR report. Note: these are laboratory susceptibility results, not direct measures of treatment failure.

Significance

  • Treatment choices: When a drug works against fewer than one in five samples, doctors cannot use it as a safe empirical (first-guess) option. Region-specific data help them choose better.
  • District-level picture: Including 12 district hospitals for the first time shows that resistance is not confined to big city hospitals.
  • Newborn sepsis: High resistance in Klebsiella affects the treatment of very sick newborns, a key concern for India's child-health goals.
  • Old drugs still useful: High susceptibility to fosfomycin and nitrofurantoin for urinary E. coli offers options that spare last-resort antibiotics.
  • Health spending: Resistant infections mean longer hospital stays and costlier drugs, which add to household expenditure (see our note on National Health Accounts 2023-24).

Challenges

  • Easy access: Antibiotics are still widely sold without prescription despite Schedule H1.
  • Infection control: Hand hygiene, sterilisation and surface cleaning in many hospitals remain weak.
  • Limited diagnostics: Many facilities lack culture and susceptibility testing, so antibiotics are prescribed blindly.
  • Animal and environmental use: Antibiotics used in poultry, fisheries and dairy, and pharmaceutical effluents, also drive resistance.
  • Few new drugs: The pipeline of new antibiotics is thin worldwide.

Way forward

As recommended in the report:

  • Strengthen infection prevention and control in hospitals.
  • Expand access to laboratory testing so that treatment follows susceptibility results.
  • Protect last-resort antibiotics like carbapenems through antimicrobial stewardship.
  • Avoid indiscriminate use of fluoroquinolones (such as ciprofloxacin) for bacterial diarrhoea.
  • Use region-specific treatment guidelines and give priority to early diagnosis of newborn sepsis.

Beyond the report, a One Health approach linking human, animal and environmental surveillance — the logic behind measures such as India's indigenous H5N1 poultry vaccine — remains central.

Facts for Prelims

  • AMRSN = Antimicrobial Resistance Surveillance and Research Network of ICMR.
  • 2025 report: 30 tertiary + 34 secondary hospitals; 12 district hospitals included for the first time.
  • Carbapenems (meropenem, imipenem, ertapenem) are "last-resort" antibiotics.
  • MRSA = methicillin-resistant Staphylococcus aureus.
  • World AMR Awareness Week is observed every year from 18 to 24 November.

Mains practice question

"Antimicrobial resistance is a silent pandemic that needs a One Health response." Discuss in the light of the findings of ICMR's AMR surveillance report for 2025. (250 words)

FAQs

What is the ICMR AMR surveillance report 2025?

It is the annual report of ICMR's Antimicrobial Resistance Surveillance and Research Network, covering samples collected in hospitals from January to December 2025.

Which bacterium shows the highest carbapenem resistance in the report?

Acinetobacter baumannii, with about 91.1% of tested samples resistant to carbapenems.

What is new in this edition?

For the first time, data from 12 district hospitals were included, as part of 34 secondary-care hospitals.

Do these figures mean treatment has failed in these patients?

No. The figures are laboratory susceptibility results; they guide treatment choices but do not directly measure patient outcomes.

Sources

  • ICMR – AMRSN Annual Report 2025 (PDF)
  • ICMR – AMRSN Annual Report 2024 (PDF, for comparison)
  • The South First – Several antibiotics fail against common infections, ICMR report finds
  • Daijiworld – Antibiotic resistance rises in India, ICMR report flags growing threat
#antimicrobial resistance India#AMRSN annual report#carbapenem resistance Klebsiella#World AMR Awareness Week 2026#UPSC science and health
Ankit Kumar
AuthorAnkit KumarFounder & Editor, Tathyo

Ankit Kumar is the founder and editor of Tathyo. He works with BPSC and UPSC aspirants at GS Hub, Patna. At Tathyo, he oversees fact-checking so every article is exam-relevant and based on official sources.

Read also

विज्ञान
Science & Tech

Voyager 1 Reaches One Light-Day from Earth: A Milestone 49 Years in the Making

On 18 November 2026, NASA's Voyager 1 became the first human-made object to reach one light-day from Earth — about 25.9 billion km — so a radio command now takes a full 24 hours to reach it.

Ankit Kumar · 7 min · 19 Nov 2026
विज्ञान
Science & Tech

India's First Indigenous H5N1 Bird Flu Vaccine for Chickens: ICAR-NIHSAD Vaccine to Be Dedicated to the Nation on 20 November

ICAR-NIHSAD, Bhopal has developed India's first indigenous inactivated vaccine against H5N1 clade 2.3.2.1a for chickens. Shivraj Singh Chouhan is scheduled to dedicate it to the nation on 20 November 2026. Key facts, the current culling policy, the One Health angle and challenges.

Ankit Kumar · 8 min · 18 Nov 2026
विज्ञान
Science & Tech

India's Space Sector Reforms: Opening the Skies to Private Firms and the Success of Vikram-1

From the 2020 reforms to IN-SPACe, the Space Policy 2023 and liberal FDI rules, India's space sector is open to private players. In July 2026 Skyroot's Vikram-1 made the country's first private orbital launch.

Ankit Kumar · 7 min · 17 Nov 2026